References
Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet London Engl. 2016;388:248–57.
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet London Engl. 2017;389:1011–24.
Ishido K, Kimura N, Wakiya T, et al. Development of a biomarker-based scoring system predicting early recurrence of resectable pancreatic duct adenocarcinoma. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10866-6
Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol. 2019;37(Suppl 4):189.
Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38:1763–73.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
There are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ishido, K., Kimura, N., Wakiya, T. et al. ASO Author Reflections: Reconsidering the Treatment Strategy for Resectable Pancreatic Cancer Using a Biomarker-Based Scoring System for Prediction of Early Recurrence. Ann Surg Oncol 29, 1294–1295 (2022). https://doi.org/10.1245/s10434-021-10920-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-10920-3